ASCO26 Podcast: an analyst rundown of the best readouts and key trends
While the 2026 American Society of Clinical Oncology (ASCO) conference may be over for another year, the editorial team at…
Oncology
-
-
ASCO 2026: Interim data released for upcoming BRAF and RAS mCRC therapies
Several abstracts and data presentations on emerging clinical research in metastatic colorectal cancer (mCRC) prompted expert interest and discussion at…
-
Rezolute’s stock up on interim Phase III tumour HI data
Rezolute’s second Phase III trial of ersodetug, this time in tumour hyperinsulinism (HI), is yielding more promising data, prompting the company’s…
-
ASCO26: In vivo oncology approaches continue to show promise
As the American Society for Clinical Oncology (ASCO) meeting of 2026 has drawn to a close, experts are still sifting…
-
ASCO26: RevMed’s daraxonrasib presents a turning point for pancreatic cancer
At the 2026 American Society of Clinical Oncology (ASCO) annual congress, topline data from the Phase III RASolute 302 was…
-
ASCO26: Cancer vaccines and at-home injectable drugs continue to show promise
During the American Society of Clinical Oncology (ASCO) meeting 2026, data were presented for a number of cancer vaccines, including…
-
ASCO26: key readouts in lung cancer
As professionals from across the oncology landscape gather at the 2026 American Society of Clinical Oncology (ASCO) congress in Chicago,…
-
ASCO26: BMS and J&J debut shining multiple myeloma data
Several companies have presented compelling data from multiple myeloma studies at the 2026 American Society of Clinical Oncology (ASCO) meeting.…
-
MSD’s sac-TMT meets primary endpoints in Phase III endometrial cancer trial
MSD’s TROP2-directed antibody-drug conjugate (ADC), sac-TMT, has shown benefit in both overall survival (OS) and progression-free survival (PFS) in a…
-
New findings link common pesticide to early-onset colorectal cancer
The World Health Organization cites colorectal cancer (CRC) as the second leading cause of cancer-related deaths worldwide. Although it predominantly…
